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Background: Landiolol hydrochloride is a new β-adrenergic blocker with a pharmacological profile that suggests it
can be administered safely to patients who have sinus tachycardia or tachyarrhythmia and who require heart rate
reduction. This study aimed to investigate whether intraoperative administration of landiolol could reduce the
incidence of atrial fibrillation (AF) after cardiac surgery.
Methods: Of the 200 consecutive patients whose records could be retrieved between October 2006 and
September 2007, we retrospectively reviewed a total of 105 patients who met the inclusion criteria: no previous
permanent/persistent AF, no permanent pacemaker, no renal insufficiency requiring dialysis, and no reactive airway
disease, etc. Landiolol infusion was started after surgery had commenced, at an infusion rate of 1 μg/kg/min,
titrated upward in 3–5 μg/kg/min increments. The patients were divided into 2 groups: those who received
intraoperative β-blocker therapy with landiolol (landiolol group) and those who did not receive any β-blockers
during surgery (control group). An unpaired t test and Fisher’s exact test were used to compare between-group
differences in mean values and categorical data, respectively.
Results: Seventeen of the 105 patients (16.2%) developed postoperative atrial fibrillation: 5/57 (8.8%) in the
landiolol group and 12/48 (25%) in the control group. There was a significant difference between the two groups
(P=0.03). The incidence of AF after valve surgery and off-pump coronary artery bypass grafting was lower in the
landiolol group, although the difference between the groups was not statistically significant.
Conclusions: Our retrospective review demonstrated a marked reduction of postoperative AF in those who
received landiolol intraoperatively. A prospective study of intraoperative landiolol for preventing postoperative atrial
fibrillation is warranted.
Keywords: β-blocker, Landiolol, Postoperative atrial fibrillation, Cardiac surgeryBackground
Atrial fibrillation (AF) is the most common arrhythmic
complication after cardiac surgery, with an incidence of
approximately 20% to 50% that has not changed despite
improvements in anesthesia, surgical techniques, and
drug therapy [1]. This is probably due to co-morbidities
including older age, left ventricular dysfunction, chronic
pulmonary disease, and renal insufficiency, which are also* Correspondence: n-kazu@nms.ac.jp
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reproduction in any medium, provided the orcontributors to postoperative AF [2,3]. AF has also been
associated with a complicated postoperative course, in-
creased incidence of stroke, increased intensive care unit
and total hospital stays, and increased health care costs
[2-5].
Prophylaxis with preoperative β-blocker therapy [1],
preoperative amiodarone [6], and postoperative atrial pa-
cing [7] has had varying degrees of clinical impact, but
recent reviews reflect a growing consensus in favor of
prophylactic administration of β-blockers [8,9]. The la-
test American College of Chest Physicians guidelines forral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ter cardiac surgery recommended that strong consider-
ation should be given to the prophylactic administration
of β-blockers as means of lowering the incidence of
new-onset post-cardiac surgery AF (strength of recom-
mendation, A; evidence grade, fair, net benefit, substantial)
[8]. However, the role of intraoperative β-adrenergic
blockers in preventing postoperative AF is still unknown.
Landiolol hydrochloride is a new β-adrenergic blocker
synthesized by Ono Pharmaceutical Co. (Osaka, Japan)
that resembles esmolol, but has a greater β1-selectivity
and a shorter elimination half-life [10,11]. Landiolol is
metabolized very quickly by serum pseudocholinesterase
and carboxyesterase in the liver to an inactive metabolite
with a half-life of 4 min in healthy human subjects [10].
Renal and hepatic clearance do not contribute to the
pharmacokinetics at clinical concentrations, which makes
landiolol titratable, and the onset and offset of action are
rapid [10]. Landiolol has a higher β1-selectivity than any
currently available β-blocker, but has neither intrinsic
sympathomimetic activity nor significant membrane-
stabilizing activity [10-13]. Landiolol may suppress
ventricular and supraventricular arrhythmias [13-15]. The
superior pharmacological profile of landiolol may allow
for safer use in patients in the acute phase of severe heart
disease and in other clinical settings [15]. Therefore, we
undertook a retrospective, single-institution study to de-
termine if intraoperative administration of landiolol re-
duces the incidence of AF after cardiac surgery.
Methods
We reviewed the records of 200 consecutive patients
who underwent elective coronary and/or valve surgery
at our institution between October 2006 and September
2007, and who were managed by senior anesthesiologists
and cardiologists. (This should signify that the subjects
were patients who underwent cardiac surgery performed
by surgeons from the same cardiac surgery department,
in succession, during a one-year period between October
2006 and September 2007). Patients with previous per-
manent/persistent AF, a permanent pacemaker, renal in-
sufficiency requiring dialysis and reactive airway diseases
were excluded from the analysis, as were those who re-
ceived amiodarone as initial therapy for AF before initi-
ation of β-blocker therapy. Patients with prior AF were
not excluded if they presented for surgery in sinus rhy-
thm without amiodarone therapy. A total of 105 patients
met these criteria for review. Infusions of landiolol were
started after the beginning of surgery, at the discretion
of the attending senior anesthesiologist. Infusion of land-
iolol was initiated at an infusion rate of 1 μg/kg/min and
titrated upward in 3–5 μg/kg/min increments based on
heart rate (HR) and blood pressure responses. The pa-
tients were divided into 2 groups: those who receivedintraoperative β-blocker therapy with landiolol (landiolol
group) and those who did not receive any β-blockers du-
ring surgery (control group). After surgery, each patient
was admitted to the intensive care unit (ICU) and was
subsequently transferred to the ward. The patients were
continuously monitored during the first 72 h after sur-
gery, using bedside monitors that were alarm-triggered.
Thereafter all patients were monitored routinely with an
alarm-triggered three lead telemetry system until the
morning of postoperative day 7. Postoperative β-blocker
therapy (landiolol, carvedilol or atenolol) was used at the
discretion of the attending senior anesthesiologists and
cardiologists in the ICU. Patients with and without diabe-
tes with persistently elevated serum glucose (>180 mg/dL)
received IV insulin infusions to maintain serum gluco-
se <180 mg/dL for the duration of ICU care. The serum
levels of potassium and other electrolytes were monitored
and maintained within the normal range. An unpaired t
test and Fisher’s exact test were used for comparison of
between-group differences in mean values and categorical
data, respectively. This study was approved by the ethics
committee of Nippon Medical School. The committee has
established that retrospective studies involving analysis of
medical records can be conducted without informed con-
sent from the subjects.Results
Clinical characteristics and perioperative data are shown
in Table 1. There were no statistically significant diffe-
rences between the landiolol and control groups in age,
New York Heart Association (NYHA) class, history of
hypertension, type of surgery, ejection fraction or pre-
operative β-blocker use. Overall, 17 of 105 patients
(16.2%), 5 of 57 (8.8%) in the landiolol group and 12 of
48 (25%) in the control group, developed postoperative
AF (P = 0.03). In the landiolol group, AF developed in 2
patients on postoperative day 2, in 1 patient on post-
operative day 3, and in 2 patients on postoperative day
4. The mean duration of landiolol administration was
23.9 ± 32.0 h. In addition, the time of AF onset after ad-
mission to the ICU was 3.0 ± 1.2 days in the intraopera-
tive landiolol group, and 2.2 ± 1.0 days in the group that
did not receive landiolol. Although the difference was
not significant, onset tended to be delayed in the intrao-
perative landiolol group. Postoperative β-blockers were
more frequently used in the landiolol group than in the
control group (P < 0.0001). The patients in the landiolol
group showed a trend toward shorter times to extuba-
tion and length of ICU stay, but the differences between
the groups were not statistically significant. There were
no differences between the groups in blood glucose or
potassium levels, and there were no significant differ-
ences in postoperative complications.
Table 1 Clinical characteristics and perioperative data for the landiolol and control groups
Control Landiolol P value
(n=48) (n=57)
Age (yr) 65.7 ± 12.6 67.2 ± 11.5 NS
NYHA class 1.9 ± 0.7 1.9 ± 0.7 NS
BMI 23.0 ± 4.1 23.0 ± 3.4 NS
Hypertension 38 (79.2) 47 (82.4) NS
Diabetes 14 (29.2) 18 (31.6) NS
Hyperlipidemia 18 (37.5) 25 (43.9) NS
Previous CHF 22 (45.8) 23 (40.4) NS
Previous MI 7 (14.6) 12 (21.1) NS
Previous AF 8 (16.7) 10 (17.5) NS
LV Ejection fraction (%) 60.5 ± 14.7 56.4 ± 15.2 NS
Preoperative ACE inhibitor use 38 (79.2) 37 (64.9) NS
Preoperative β-blocker use 24 (50.0) 29 (50.9) NS
Postoperative β-blocker use 16 (33.3) 41 (71.9) <0.0001
Preoperative Cr (mg/dL) 1.1 ± 1.8 1.3 ± 1.6 NS
Preoperative % VC 95 ± 21 94 ± 19 NS
Preoperative FEV 1.0% 82 ± 15 82 ± 14 NS
On-pump CABG 5 (10.4) 9 (15.8) NS
Off-pump CABG 14 (29.2) 27 (47.4) NS
Valve surgery
AVR 16 (33.3) 12 (21.1) NS
MVR 3 (6.3) 2 (3,5) NS
MVP 9 (18.8) 6 (10.5) NS
TVP 1 (2.1) 1 (1.8) NS
Operating time (min) 344 ± 78 334 ± 86 NS
Blood loss (mL) 1159 ± 1036 1197 ± 1246 NS
Fluid and blood infusion volume (mL) 5471 ± 1657 5405 ± 1948 NS
Urine volume (mL) 1283 ± 933 1270 ± 948 NS
No. of patients receiving intraoperative remifentanil 32 (66.7) 39 (68.4) NS
Intraoperative remifentanil dose (μg/kg/min) 0.18 ± 0.06 0.21 ± 0.07 NS
Postoperative AF 12 (25.0) 5 (8.8) 0.02
Time of onset of new AF (d) 2.2 ± 1.0 3.0 ± 1.2 NS
Length of ICU stay (d) 3.5 ± 2.0 3.0 ± 2.1 NS
Time to extubation (hr) 20.9 ± 41.6 16.0 ± 29.1 NS
Postoperative complications
Pulmonary edema 6 (12.5) 7 (12.3) NS
Stroke 1 ((2.1) 0 NS
Seizures 1 (2.1) 1 (1.8) NS
Renal failure 0 1 (1.8) NS
Values are shown as numbers (%) or as the mean ± SD. The unpaired t-test was used for comparison of between-group differences in means. Fisher’s exact test
was used for comparison of between-group differences in categorical data. NYHA: New York Heart Association, CHF: congestive heart failure, MI: myocardial
infarction, LV: left ventricular, ACE: angiotensin-converting enzyme, Cr: creatinine, AF: atrial fibrillation, ICU: intensive care unit.
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Table 2 Systolic and diastolic blood pressure and heart rate in the two groups
Group Before induction After induction Start of operation Sternotomy End of operation
SBP (mm Hg) Control 136 ± 18 88 ± 12 115 ± 19 128 ± 15 115 ± 19
Landiolol 139 ± 24 93 ± 13 120 ± 19 137 ± 18* 118 ± 19
DBP (mm Hg) Control 69 ± 16 44 ± 7 56 ± 11 63 ± 12 54 ± 9
Landiolol 72 ± 17 46 ± 10 58 ± 14 65 ± 15 56 ± 11
HR (beats/min) Control 68 ± 12 54 ± 10 59 ± 11 65 ± 8 76 ± 9
Landiolol 70 ± 12 58 ± 13 63 ± 11* 71 ± 12* 75 ± 15
Values are shown as the mean ± SD. *P<0.05 vs. control (unpaired t-test). SBP: systolic blood pressure, DBP: diastolic blood pressure, HR: heart rate.
Repeated measures ANOVA showed significant differences between the groups for SBP (p=0.03) and HR (p=0.02). SBP was significantly higher in the landiolol
group at the start of the operation. SBP and HR were significantly higher in the landiolol group at sternotomy. DBP was similar in both groups.
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blood pressure (DBP), and HR are shown in Table 2. In
the landiolol group SBP was significantly higher at the
start of the operation and SBP and HR were significantly
higher at sternotomy, compared to the control group.
The incidences of AF after valve surgery and off-pump
coronary artery bypass grafting (CABG) were lower in
the landiolol group (Table 3), but the differences bet-
ween the groups were not statistically significant. The pe-
rcentage incidence of postoperative AF was similar among
all operative procedures (Table 3).
The data in Table 4 suggest a lower incidence of
postoperative AF in patients who received postoperative
β-blocker therapy (12.3%, 7 of 57 patients) compared
with those who did not receive this therapy (20.8%, 10 of
48 patients). However, this difference was not statisti-
cally significant. Of 57 patients in the landiolol group,
β-blocker therapy (landiolol, carvedilol or atenolol) was
continued postoperatively in 41 and discontinued after
surgery in 16. There was no significant difference in the
occurrence of postoperative AF between these sub-
groups (9.8% vs. 6.3%, respectively). Patients who received
β-blocker therapy only after surgery had an incidence of
postoperative AF of 18.8% (3 of 16). A higher rate of AF
was found in patients who did not receive β-blockers peri-
operatively (28.1%, 9 of 32), but the occurrence of post-
operative AF did not differ significantly among all the
sub-groups.Table 3 Comparison of the incidence of postoperative
atrial fibrillation between the landiolol and control
groups
Total population Control Landiolol P value
Valve surgery 9/50 (18%) 7/29 (24%) 2/21 (10%) 0.18
On-pump CABG 2/14 (14%) 1/5 (20%) 1/9 (11%) 0.65
Off-pump CABG 6/41 (15%) 4/14 (29%) 2/27 (7%) 0.07
All surgery 17/105 (16%) 12/48 (25%) 5/57 (8.8%) 0.02
Fisher’s exact test was used to analyze between-group differences in
categorical data. CABG: coronary artery bypass grafting.Discussion
AF is a common complication after cardiovascular sur-
gery and often results in prolonged hospital stays and
increased morbidity compared with patients who main-
tain sinus rhythm [2-5]. Approaches to preoperative and
postoperative prophylaxis of AF using selective β-blockers
[1,8,9], amiodarone [6], and atrial pacing [7] have achieved
varying degrees of clinical success. However, the role of
intraoperative β-adrenergic blockers in preventing post-
operative AF is unknown. In the present study, patients
who received intraoperative landiolol had a significantly
lower incidence of postoperative AF (8.8%).
In a study of patients who underwent on-pump CABG,
an inhibitory effect on postoperative AF was reported
from administering landiolol for 48 h from the start of
surgery [16]. The results of our study, which includes not
only on-pump CABG, but also off-pump CABG and heart
valve surgical patients, suggest that AF occurrences can be
suppressed even in these cases. Sezai et al. [16] reported
that postoperative AF was reduced by treatment with
landiolol in patients undergoing CABG on cardiopulmo-
nary bypass (10%, 7 of 70 patients). Landiolol infusion was
started at the time of central anastomosis during CABG
and discontinued after 48 h. In our study, of 57 patients in
the landiolol group, β-blocker therapy was continued
postoperatively in 41 patients and discontinued after sur-
gery in 16. The incidence of postoperative AF in pa-
tients receiving intraoperative and postoperative β-blockerTable 4 Effect of perioperative β-blockers on the







(+) (+) 4/41 (9.8%)
(+) (−) 1/16 (6.3%)
(−) (+) 3/16 (18.8%)
(−) (−) 9/32 (28.1%)
AF: atrial fibrillation. There were no significant differences in the incidence of
postoperative AF among the groups. Four of the 41 patients who received
intraoperative and postoperative β-blockers developed postoperative AF. Two
of these patients developed AF after discontinuation of postoperative
β-blocker therapy.
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study. Similarly, the incidence of postoperative AF in
patients who received landiolol only during surgery was
6.3%. Most known risk factors were found to be similar
among groups. These results suggest a possible role for
prophylactic landiolol during cardiac surgery to reduce
the incidence of postoperative AF.
In the postoperative heart, multiple factors may poten-
tially predispose a patient to AF through alterations in
refractoriness and/or local reentry. These include opera-
tive trauma from surgical dissection and manipulation,
inflammation, elevation in atrial pressure from post-
operative impaired ventricular function, chemical stimu-
lation during perioperative support with catecholamines
and other inotropic agents, reflex sympathetic activation
from volume loss, anemia or pain, parasympathetic ac-
tivation, fever from atelectasis or infection, and hypo-
glycemia or ischemic damage incurred during surgery
[17,18]. Recent studies have shown that markers of oxi-
dative injury and inflammation, such as C-reactive pro-
tein, are elevated in patients with AF, indicating that
they may have an important role in the pathogenesis of
postoperative AF [19,20]. Landiolol has a lipid pero-
xidation-reducing effect and suppresses the increase in
phospholamban serine phosphorylation in the sarcop-
lasmic reticulum (SR) in hearts subjected to ischemia-
reperfusion (I/R) [21]. Landiolol, as well as propranolol
and esmolol, also has cardioprotective effects in isolated
guinea pig hearts subjected to I/R injury [22]. Therefore,
landiolol may have anti-ischemic properties as an anti-
oxidant and via preservation of SR function during the
ischemic period. In addition, preischemic administration
of landiolol reduced cardiac cellular damage and impro-
ved the recovery of cardiac function in the rat heart
through protein kinase C (PKC) epsilon-mediated path-
way, similar to that afforded by ischemic preconditioning
[23]. Reduction of postoperative AF by landiolol may be
due to reduced inflammation or oxidative stress, or phar-
macological preconditioning effect, in addition to effective
β-blockade.
Cardiac surgery requiring cardiopulmonary bypass re-
sults in significant impairment of β-adrenergic receptor
(βAR) function [24]. This can cause depressed post-
operative myocardial function that results in atrial en-
largement, which is a risk for postoperative AF. The
possible mechanisms underlying impaired βAR function
include myocardial ischemia-reperfusion injury [25], a
hibernating and stunned myocardium [26], and acute
myocardial βAR desensitization [27,28]. A marked in-
crease in catecholamine levels found during cardiac sur-
gery resulting in agonist-induced desensitization may be
a major mechanism behind acute βAR desensitization
[27]. Increased myocardial catecholamine concentrations
may, at least in part, be the stimulus for the myocardialhyporesponsiveness seen during cardiac surgery. In sup-
port of this, blockade of βARs with low-dose βAR antag-
onist therapy improves myocardial function in congestive
heart failure [29], a clinical setting in which attenuation of
chronic βAR desensitization has been postulated as a pos-
sible mechanism. In the landiolol group SBP was signifi-
cantly higher at the start of the operation and SBP and
HR were significantly higher at sternotomy, compared to
the control group. These results suggested that serum cat-
echolamine levels in the landiolol group may increase dur-
ing surgery. Nevertheless, we found a marked reduction of
postoperative AF in the landiolol group. Landiolol may
have the suppressive effect of catecholamine-induced βAR
desensitization. Booth et al. reported that intravenous es-
molol administration during coronary artery revasculari-
zation after acute myocardial ischemia results in improved
left ventricular function immediately after cardiopulmon-
ary bypass (CPB) via enhanced βAR signaling [30], where-
as chronic oral ß-adrenergic blocker therapy in patients
undergoing CABG surgery does not protect patients from
acute βAR desensitization [27]. In addition, Cork et al. de-
monstrated improved early intermediate outcomes (such
as cardiac output) immediately post-CPB in patients re-
ceiving an intraoperative β-adrenergic blocker [31]. In a
similar manner, improvement of βAR function by intra-
operative administration of landiolol may contribute to
preserved left ventricular function and fewer inotropic
requirements postoperatively, resulting in a reduced inci-
dence of postoperative AF.
The prevalence of AF increases with worsening heart
failure from 5% in patients of NYHA class I under drug
therapy to as high as 50% in those of NYHA class IV.
Structural, electrophysiologic, and neurohumoral mech-
anisms may play important roles in this effect, but an
association of heart failure and AF has not been estab-
lished in the postoperative setting. Factors predisposing
patients to postoperative AF may be unrelated to left
ventricular function, and in our study patients who recei-
ved landiolol intraoperatively experienced less AF than
those who did not, despite having similar left ventricular
ejection fractions (56.4% vs. 60.5%). However, preoperative
left ventricular dysfunction is one of the strongest predic-
tors of mortality after CABG surgery. The use of ultra-
short-acting β-blockers has been suggested as a safe and
efficacious method for treating patients with accelerated
adrenergic drive during and after the postoperative phase
of cardiovascular surgery. Landiolol hydrochloride is ap-
proximately nine times more potent in β-blocking activity
in vivo and eight times more cardioselective in vitro than
esmolol [10]. Moreover, the suppressive effects on cardio-
vascular perforance are significantoly less potent or land-
iolol than those of esmolol at equipotent β-blocking doses
[13]. These properties facilitate a more rapid recovery af-
ter drug administration if an adverse effect develops,
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of patients undergoing cardiac surgery and in other cli-
nical settings.
Our study had several linitations. First, our patients
had undergone various cardiac procedures with or with-
out the use of a heart-lung machine. Second, they were
not randomly assigned to either group and there was a
between-group difference in the number and type of the
cardiac surgery that the patients had undergone. Third,
the optimum dose for intraoperative landiolol could not
be verified, including in our investigations. Therefore, to
confirm the preventive effect of intraoperative landiolol
on AF after cardiac surgery, a large-scale clinical study is
needed.
The main points of our findings are: (1) when landiolol
was not administered intraoperatively, the incidence of
postoperative AF was lower in the group that received
postoperative β-blockers than in the group that did not;
(2) even when postoperative β-blockers were used, the
incidence of postoperative AF was lower in the group
that received intraoperative landiolol; and (3) when land-
iolol was administered intraoperatively, the incidence of
postoperative AF was low regardless of whether or not
postoperative β-blockers were used.
Conclusions
Although this was a retrospective, nonrandomized study,
our retrospective review of 105 patients who underwent
cardiac surgery demonstrated a marked reduction in post-
operative AF (8.8%) in those who received landiolol during
surgery. In the future we expect to conduct a randomized
prospective study to investigate the inhibitory effects of
intraoperative landiolol on postoperative AF, in patients
who have undergone off-pump CABG and heart valve
surgery.
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